Drug product formulations play a crucial role in determining the magnitude of drug bioavailability. Bioavailability refers to the proportion of an administered dose that arrives the systemic circulation in an active form. Optimizing formulations can significantly boost this process, leading to more effective drug delivery and therapeutic outcomes.

Eli Lilly and Company has taken the lead in in the development and tirzepatide, a groundbreaking medication for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant capacity to improve glycemic control and reduce heart disease. The complex manufacturing process of tirzepatide requires a series of meticulous